Drug is first PARP inhibitor shown to be effective in both patients with and without a BRCA mutation
News
EMA facing higher-than-expected staff losses after Brexit
Executive Director Guido Rasi says that hitting 19% staff loss figure will be “very challenging”
Roche ends development of olesoxime after “many difficulties”
The company acquired the spinal muscular atrophy drug from Trophos for €120 million in 2015
Antibiotic supply chains on ‘brink of collapse’
Access to Medicine Foundation warns that urgent action is needed to rebuild the antibiotics market
Pfizer’s Xalkori makes it onto Cancer Drugs Fund
NICE has said that evidence is limited for the drug’s effectiveness in treating ROS1-positive lung cancer
FDA approves Pfizer’s Xeljanz for ulcerative colitis
The oral therapy is the first and only Janus kinase (JAK) inhibitor approved in the US for this patient population
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Priority review for Astellas’ AML drug
Astellas Pharma’s gilteritinib is under priority review in the US as potential treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.
Bayer/Loxo’s larotrectinib gets speedy review in the US
Bayer/Loxo Oncology’s larotrectinib has been granted a priority review by the US Food and Drug Administration, which will consider its use to treat metastatic solid tumours carrying a certain genetic mutation.
Trial to test cancer combo in both adults and children
UK researchers have launched an early stage trial designed to help assess whether AstraZeneca and MSD’s selumetinib could be effective in combination with dexamethasone as a treatment for leukaemia.
NHS England unveils £10m fund to retain GPs
NHS England has announced a new initiative to help retain GPs in the shape of a £10 million fund designed to capture those considering leaving general practice
US approves UCB’s Cimzia for psoriasis
Drug is the first Fc-free, PEGylated anti-TNF treatment option for this indication and marks UCB’s entry into immuno-dermatology
AB Sciences decides against re-examination of masitinib filing
Firm says re-examination procedure “would not be the most appropriate format” to address all concerns raised by the CHMP
Janssen terminates Darzalex/Tecentriq combo trial
Drug fails to show any benefit over Tecentriq alone in lung cancer.
Health and pharma link to tackle dementia in Greater Manchester
Partnership between Health Innovation Manchester, the Greater Manchester Health and Social Care Partnership, and the Dementia Industry Group will focus on finding the best care and treatment options
